Prima BioMed replaces director
13 February, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed Pete Meyers, currently CFO of TetraLogic Pharmaceuticals, as a non-executive director to replace Dr Richard Hammel.
Last call for companies to assist with 2014 key surveys: metrics from CEOs, manufacturing and medtech in China
13 February, 2014Three key surveys are in their final weeks as biotech and medtech companies are urged to assist with views and metrics that underpin advocacy efforts and the development of industry resources.
AusBiotech responds to the review of employee share schemes
11 February, 2014AusBiotech has responded on behalf of its members to the federal government's review of employee share schemes (ESS) for start-ups, making both direct and written submissions to the review last week.
Cochlear 1H profit slumps 73%
11 February, 2014 by Dylan Bushell-EmblingCochlear (ASX:COH) has blamed delays receiving anticipated regulatory approval for new products and the potential costs of a patent violation lawsuit on a steep decline in 1H14 net profit.
Admedus gets FDA approval for CardioCel
10 February, 2014 by Dylan Bushell-EmblingThe US FDA has granted marketing approval for Admedus's (ASX:AHZ) CardioCel for use in cardiac repair surgeries in adults and children.
Clinuvel's Scenesse being trialled in HHD
10 February, 2014 by Dylan Bushell-EmblingAn Italian phase II trial of Clinuvel's (ASX:CUV) Scenesse in rare skin condition Hailey-Hailey Disease has commenced, with recruitment due to be complete by March.
TGA seeks experts for advisory roles
06 February, 2014The Therapeutic Goods Administration (TGA) is seeking expressions of interest from experts in relevant clinical or scientific fields who want to contribute to the regulation of therapeutic goods in Australia.
GI Dynamics gets expanded reimbursement in Germany
05 February, 2014 by Dylan Bushell-EmblingGermany's InEk has agreed to grant NUB Status 1 to GI Dynamics' (ASX:GID) EndoBarrier Therapy, allowing hospitals to negotiate for additional funding to cover the cost of procedures.
TGA clears three surgeons to use NovoSorb BTM
04 February, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo announced that three RAH surgeons have been authorised to prescribe its NovoSorb BTM dermal scaffold in free flap donor site repair surgery.
Novotech opens South African office
04 February, 2014 by Dylan Bushell-EmblingSydney-based CRO Novotech has established a dedicated presence in South Africa, its eleventh market, in response to a growing demand for clinical services in the nation.
Calling medical device and diagnostic companies with an interest in China
04 February, 2014AusBiotech is developing resources to support Australian medical device and diagnostics companies to engage with China. AusBiotech seeks your comments in a confidential quick survey to guide the development of the most suitable resources, in order to gauge what is needed.
Phase 1 of Admedus HSV-2 trial achieves primary endpoint
03 February, 2014Admedus (ASX:AHX) has announced interim study results on its phase 1 trial of a therapeutic vaccine for herpes simplex virus (HSV-2).
Mesoblast's MPCs reduce back pain in phase II trial
30 January, 2014 by Dylan Bushell-EmblingPatients with low back pain from early disc degeneration treated with Mesoblast (ASX:MSB) MPCs during a phase II trial reported reduced back pain and required fewer pain drugs compared to controls.
Medtech event of the year open for registration
30 January, 2014The annual AusMedtech national conference will again be held in Melbourne, from 1-2 April at the Hilton on the Park. The flagship medical technology event of the year has just confirmed Mick Farrell, CEO of ResMed, to speak on day one.
Calzada scores licence deal for AOD9604
28 January, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) subsidiary Metabolic has secured the first of what it hopes will be a number of licensing agreements with Australian compounding pharmacies for its peptide drug AOD9604.
